Check-Cap provides corporate update.

2015 United States Sub-Plan to the 2015 Equity Incentive Plan for U.S. Tax purposes; and to approve the conditions of engagement of Mr. William Densel, as CEO.. Check-Cap provides corporate update, reports financial outcomes for second quarter 2015 Check-Cap Ltd. , a medical stage medical diagnostics organization engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, supplied a corporate update and announced financial results for the next quarter today, ended June 30, 2015. ‘We are encouraged by the progress we have made in recent months, like the effective imaging of significant polyps in a variety of anatomical segments of the colon clinically,’ said Man Neev, CEO of Check-Cap.By more specifically narrowing the pool of individuals treated with FOLFOX plus Vectibix to people that have wild-type RAS, greater improvements in general survival and progression-free of charge survival were noticed. Specifically, previous data discovered that OS was improved by 4.4 months in individuals with wild-type KRAS. By further narrowing to individuals with wild-type RAS, a noticable difference in OS of 5.8 months was observed. In individuals with wild-type RAS, OS was 26.0 months and 20.2 months and PFS was 10.1 months and 7.9 months in the Vectibix in addition FOLFOX arm when compared to FOLFOX alone arm, respectively. BRAF mutations weren’t observed to possess predictive worth.25, 95 % CI, 1.02-1.55) and PFS were seen in the Vectibix as well as FOLFOX arm when compared to FOLFOX alone arm.